Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Tivic Health Systems Inc (TIVC)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/10/2025: TIVC (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
Analysis of Past Performance
Type Stock | Historic Profit -46.17% | Avg. Invested days 44 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/10/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 3.68M USD | Price to earnings Ratio - | 1Y Target Price 210 |
Price to earnings Ratio - | 1Y Target Price 210 | ||
Volume (30-day avg) - | Beta 2 | 52 Weeks Range 2.43 - 16.08 | Updated Date 06/29/2025 |
52 Weeks Range 2.43 - 16.08 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.05 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -2151.43% |
Management Effectiveness
Return on Assets (TTM) -100.63% | Return on Equity (TTM) -218.77% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1673245 | Price to Sales(TTM) 7.12 |
Enterprise Value 1673245 | Price to Sales(TTM) 7.12 | ||
Enterprise Value to Revenue 3.24 | Enterprise Value to EBITDA 0.16 | Shares Outstanding 965899 | Shares Floating 765790 |
Shares Outstanding 965899 | Shares Floating 765790 | ||
Percent Insiders 12.81 | Percent Institutions - |
Upturn AI SWOT
Tivic Health Systems Inc
Company Overview
History and Background
Tivic Health Systems Inc. was founded to develop and commercialize bioelectronic therapies. They focus on non-invasive neuromodulation devices for treating conditions like sinus pain and inflammation. Their primary product is ClearUP.
Core Business Areas
- Neuromodulation Devices: Develops and sells non-invasive bioelectronic devices for treating sinus and nasal conditions.
Leadership and Structure
The leadership team includes individuals with experience in medical device development and commercialization. The company has a typical organizational structure for a small cap medical device firm, involving R&D, manufacturing, sales, and marketing departments.
Top Products and Market Share
Key Offerings
- ClearUP: ClearUP is a non-invasive, over-the-counter device used to relieve sinus pain and congestion. Market share data is difficult to obtain precisely, but it competes with traditional nasal sprays and other sinus relief products. Key competitors include drug manufacturers like Johnson & Johnson (sinus medication).
Market Dynamics
Industry Overview
The market for sinus and nasal relief products is large and competitive, with a mix of pharmaceutical and device-based solutions. The trend towards non-drug therapies is growing.
Positioning
Tivic Health positions itself as a provider of drug-free alternatives for sinus relief, targeting consumers seeking non-pharmaceutical solutions.
Total Addressable Market (TAM)
The TAM for sinus and nasal congestion relief is estimated in billions of dollars annually. Tivic Health is capturing a very small segment of this large market with potential for growth in the non-pharmaceutical sector.
Upturn SWOT Analysis
Strengths
- Drug-free alternative
- Non-invasive treatment
- FDA cleared
- Over-the-counter availability
Weaknesses
- Limited market share
- Relatively new product
- Requires consumer education
- Dependence on ClearUP sales
Opportunities
- Expanding product line
- Increasing awareness of bioelectronic medicine
- Partnerships with healthcare providers
- Geographic expansion
Threats
- Competition from established pharmaceutical companies
- Changing consumer preferences
- Regulatory hurdles
- Potential for new technologies to emerge
Competitors and Market Share
Key Competitors
- JNJ
- AVNS
Competitive Landscape
Tivic Healthu2019s primary advantage is its drug-free, non-invasive approach. Disadvantages include limited market share and brand recognition compared to established pharmaceutical companies.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is dependent on financial data; Tivic Health is a small cap company with limited history on the public market.
Future Projections: Future growth projections need to be determined based on analyst estimates and the company's strategic plans.
Recent Initiatives: Need to find information on any recent strategic initatives undertaken by the company.
Summary
Tivic Health Systems Inc. offers a novel, drug-free solution for sinus pain, but faces challenges including limited market share and intense competition from established pharmaceutical companies. Expanding its product line, increasing brand awareness, and securing partnerships with healthcare providers are crucial for future growth. Financial stability is important for long-term success, as well as watching the competitors.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market data is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Tivic Health Systems Inc
Exchange NASDAQ | Headquaters Fremont, CA, United States | ||
IPO Launch date 2021-11-11 | Co-Founder, CEO & Director Ms. Jennifer Ernst | ||
Sector Healthcare | Industry Medical Devices | Full time employees 7 | Website https://tivichealth.com |
Full time employees 7 | Website https://tivichealth.com | ||
Tivic Health Systems, Inc., a health tech company, develops and commercializes bioelectronic medicine. Its primary product is ClearUP, a bioelectronic medicine for use in the treatment of sinus pain, pressure, and congestion. The company sells its products through online retailers and commercial distributors, as well as its own website. Its lead product candidate is Entolimod, a late-stage TLR5 agonist for use in the treatment of acute radiation syndrome. In addition, the company markets its commercial product under the ClearUP Sinus Pain Relief brand name. It also focusses on non-invasive vagus nerve stimulation. The company was incorporated in 2016 and is based in Fremont, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.